JP3274730B2 - Drug-containing substance for long-term heat evaporation and heat evaporation method of medicine using the same - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a drug-containing substance for long-term heat evaporation and a method for heat-evaporation of a drug using the same, and more particularly, to insecticide, sterilization, deodorization, aroma, etc.
A drug-containing substance for heat evaporation containing a drug alone or with a minimum necessary solvent, and heating for directly or indirectly heating the drug-containing substance to stably evaporate the drug over a long period of time. It relates to the transpiration method. Here, “long term” means intermittent or continuous for a total of about 15
It refers to the case where heating can be used for 0 hour or more.

[0002]

2. Description of the Related Art Conventionally, a method of heating and evaporating a solid, liquid or paste-like drug using a heating element has been known as a heat-evaporation preparation. It is an electric mosquito trap. The electric mosquito trap is used for insecticide or the like by placing an insecticide mat containing a drug on a heating plate that is electrically heated and evaporating the drug. A material in which a drug is held on a base material such as a fiberboard mainly composed of pulp or asbestos is used.

[0003] In the method of heat evaporation of this kind of insecticidal mat typified by an electric mosquito trap, there is a problem how to adjust the decomposition and evaporation rate of the drug component to stably evaporate the drug. Conventionally, various compounds are known as sustained-release agents for controlling the transpiration of drug components, for example, piperonyl butoxide, pyrethroid insecticides, paraffins, olive oil, oils and fats such as peanut oil and the like. It has been proposed to add a repellent such as water-added oils, diethyltoluamide or the like, or certain surfactants to release the oil slowly. On the other hand, as a method for suppressing the decomposition of the active ingredient, the compounding of an antioxidant is generally known, and JP-A-53-121927 discloses various effective antioxidants.

[0004] These measures, however, are 8 to 10
The present invention relates to heat evaporation of an insecticidal mat intended to be used for a very short time of about an hour, and is not sufficient for a long-time heating use. That is, the above-described method for controlling the evaporation of the drug component is to suppress the evaporation of the drug by adding a substance such as a surfactant or an antioxidant having a lower vapor pressure than the drug to be evaporated, thereby suppressing the evaporation of the drug. In order to obtain the effect, a large amount of a surfactant, an antioxidant and the like are blended. Therefore, in the early stage of use, an appropriate transpiration suppression effect is obtained, and stable drug transpiration is obtained.However, in a long-time heating use, as the drug evaporates and disappears, a surfactant or an oxidizing agent is obtained. Since the concentration of the inhibitor is increased and the effect of suppressing transpiration is enhanced, transpiration of the drug is significantly suppressed, and the residual ratio of the drug is increased. Also, despite the use of 8 to 10 hours, about 40% of the drug evaporates in the initial 2 hours,
In the remaining 6 to 8 hours, about 50% of transpiration was performed, and in the latter half, the amount of drug transpiration per unit time was remarkably reduced, and the transpiration was not stable.

[0005] As a measure to avoid the above-mentioned problems and obtain a stable vaporization of the drug over a long period of time, a part of the heated vaporized body is immersed in the chemical solution to absorb the chemical liquid into the heated vaporized body. In addition, various methods have been proposed for heating and evaporating the absorbed chemical by heating the upper portion thereof, that is, a so-called chemical absorption type heat evaporation method. And in such a chemical liquid absorption type heat evaporation method, a heat evaporation body molded from inorganic powder is used as an example,
In addition, as a method of producing such a heat evaporation body,
A method of kneading an inorganic powder and a binder such as starch, a semi-synthetic cellulose derivative, and carboxymethyl cellulose (CMC) together with water or hot water and extruding the mixture is generally used (see JP-B-61-23163). ).

[0006] However, the chemical solution used in the above-mentioned heat evaporation method is generally an organic solvent solution. For example, in the case of an insecticide solution, it is generally composed of a hydrocarbon solution such as n-paraffin containing a fixed concentration of a pyrethroid drug. Are on the market. However, the hydrocarbon-based solvent has a disadvantage that it is very easy to burn and easily causes a fire. In recent years, destruction of the ozone layer and air pollution have become a problem on a global scale due to chlorofluorocarbons and volatile organic compounds, but in the case of a chemical liquid absorption type, for example, in a commercial product, it is essentially unnecessary for insecticidal purposes. 9 solvents such as certain hydrocarbon solvents
More than a percentage are included. Therefore, reducing this solvent is an important issue. Furthermore, in the case of the chemical liquid absorption type, the internal pressure in the chemical liquid container fluctuates due to fluctuations in temperature, atmospheric pressure, and the like, causing liquid leakage, and contamination with the chemical liquid may occur during use or storage. In addition, the heat absorption and evaporation method of the chemical liquid absorption type, in order to evaporate the chemical liquid containing the solvent,
Considering the thermal efficiency, it can be said that unnecessary heat is required because not only the chemicals but also the solvent are evaporated. Furthermore, in the heat absorption and evaporation method of the chemical liquid absorption type, immediately after use,
It has a drawback that the amount of drug evaporated is not stable.

Accordingly, an object of the present invention is to solve the above-mentioned problems, to minimize the use of solvents,
Alternatively, it contains a high-concentration drug component containing the minimum necessary solvent, hardly causes clogging during heating use, and is a stable quality heat-evaporation drug that can effectively evaporate a sufficient drug for a long period of time. It is to provide an inclusion. Furthermore, an object of the present invention is to directly or indirectly heat a drug-containing substance coated with and impregnated with a drug during heating and evaporation of the drug, thereby suppressing thermal decomposition of the drug and deterioration such as clogging of the drug-containing substance, It is an object of the present invention to provide a method which is excellent in an effective volatilization rate, can stably evaporate a drug over a long period of time from the initial stage of use, and in which, for example, in the case of an insecticide, a prompt insecticidal effect can be obtained immediately after starting heating.

[0008]

According to the present invention, in order to achieve the above object, an inorganic powder having good chemical resistance and / or
Or, an organic powder , and one or more heat-evaporable drug components alone or 10 parts by weight or less based on 100 parts by weight of the drug component
With the proportion of the solvent, and stability improver to drugs heat
To stearyl-β- (3,5-di-t-butyl-4-
(Hydroxyphenyl) propionate, 2,2′-methylenebis (4-methyl-6-t-butylphenol) ,
4,4'-thiobis (3-methyl-6-t-butylphenol) , tetrakis- [methylene-3- (3 ', 5'
-Di-t-butyl-4'-hydroxyphenyl) propionate] methane , triethylene glycol-bis [3
-(3-t-butyl-5-methyl-4-hydroxyphenyl) propionate], 1,6-hexanediol-
Bis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionate], N, N'-hexamethylenebis (3,5-di-t-butyl-4-hydroxy-hydrocinnamamide ), 2,2-thio-diethylenebis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionate] , tris- (3,5-di-t-
Butyl-4-hydroxybenzyl) - isocyanurate DOO
Mixtures containing at least one compound selected pressurized et al
The present invention provides a drug-containing material for long-term heat evaporation characterized by being a press-formed product of the above. Further, according to the present invention, there is provided a method of heating and evaporating a medicine, wherein the surface of the heat-evaporating medicine-containing body is heated to a temperature of 50 to 150 ° C by a direct or indirect heating method.

[0009]

The drug-containing substance for long-term heat evaporation according to the present invention contains the above-mentioned specific compound and is composed of an inorganic powder and / or an organic powder having good chemical resistance as a base material. Is a solid drug-containing substance obtained by adding a drug component as it is or by dissolving it in a minimum necessary amount of solvent, and then adding, coating, dipping or the like by an appropriate method. Therefore, by using the heat-evaporation drug-containing substance of the present invention, the drug component can be contained at a high concentration, and can be directly or indirectly heated by a heating element, and in any case, The drug can be evaporated over a long period of time with a high effective volatilization rate.

[0010] When the solid drug-containing substance is heated directly or indirectly to evaporate the drug,
The drug evaporates mainly from the heated portion of the drug-containing body, and accordingly the drug moves from a portion other than the heated side of the drug-containing body to the heated side portion, that is, from a high concentration region to a low concentration region of the drug. I do. For this reason, a sufficient supply of the medicine is performed for the evaporation of the medicine, and the medicine is stably evaporated over a long period of about 150 hours or more instead of about 8 hours as in the conventional insecticidal mat. Therefore, it is difficult to apply the technical idea of suppressing the evaporation of a drug, which is the conventional aim of adding a sustained-release agent. In addition, the drug-containing substance of the present invention is different from the conventional heat absorption and evaporation method of a chemical liquid absorption method in that the solvent is not used or is used to a minimum necessary amount. The drug component always exists in the heated portion of the drug-containing body. However, drugs are generally unstable to heat,
If a large amount of drug is present in the heated portion, clogging is caused in a long-time heating use, which is a factor that prevents stable drug evaporation.

The present inventors have conducted intensive studies on phenomena and problems peculiar to the method of heating and evaporating a drug using the above-mentioned solid drug-containing substance. As a result, the present inventors have found that inorganic powder and / or inorganic powder having good heat resistance and chemical resistance are obtained. An organic powder is selected and used as a base material, and the above-mentioned specific compound is contained at a ratio of 10 parts by weight or less per 100 parts by weight of a drug contained therein to constitute a drug substance for heat evaporation, and furthermore, a drug component The surface temperature is selected depending on the type of the agent to be used, but the surface temperature of the agent is increased by heating to 50 to 150 ° C. (about 150 hours or more).
It has been found that stable transpiration can be obtained over the entire range, and the present invention has been completed. Therefore, a first feature of the present invention is that the solid heat-evaporating drug-containing substance that can be used for a long time of about 150 hours or more can improve the heat stability of the drug. Is used in such a quantitative ratio that does not cause transpiration of the drug. That is, in the present invention, by containing the above-mentioned specific compound in the drug-containing substance, the stability of the drug to heat is improved, clogging of the heated part of the drug-containing substance is avoided, and the length of the drug is reduced. In addition to enabling stable transpiration over a period of time, the compounding amount of the specific compound is kept low. Since only the effect is exhibited, stable transpiration for a long period of time is enabled.

Further, according to the heat-evaporation drug-containing substance of the present invention and the method of heat-evaporation of a drug using the same, a high-concentration drug containing only a drug component or a minimum necessary solvent is evaporated, so that a conventional method is used. The thermal efficiency is better than the above-mentioned heat absorption and evaporation method of the chemical liquid absorption type. That is, in the heating and evaporating method of the chemical liquid absorption type, not only the evaporating of the drug but also the evaporating of the solvent is required, so that unnecessary heat is used. In comparison,
Since the drug-containing substance of the present invention requires heat only for the evaporation of the drug, it has very good thermal efficiency. For this reason, it is possible to evaporate the medicine with a smaller amount of heat than in the case of the liquid absorption type, and as a result, it is possible to reduce the power consumption of the heating element and to save energy, and to use a small-capacity power source such as a dry battery. Becomes possible. Furthermore, it can be used at a low temperature, and the stability of the drug against heat can be further ensured. In addition, in the case of low-temperature use, the risk of burns on the heating element due to misuse is avoided, and safety is improved.

By the way, in the conventional heating-evaporation method using a chemical solution, the evaporation rate of the medicine is usually low in the initial stage of use, and it takes time until the desired effect, for example, the insecticidal effect, can be obtained. That is, in the heating and evaporating method of the chemical liquid absorption type, the liquid medicine absorbed in the heating and evaporating body is heated by the heating element, and evaporation occurs in the heated portion of the medicine-containing body. For this reason, in the early stage of use, the easily transpirable solvent in the drug solution evaporates excessively, and the amount of drug transpiration is low. Thereafter, as the time elapses, concentration of the drug occurs in the heated portion of the drug-containing body, whereby the evaporation of the drug and the evaporation of the solvent are stabilized, and the drug evaporation rate increases. In addition, even if the evaporation of the drug is stable, the rising of the evaporation of the drug immediately after energization is poor. That is, since not only the drug but also the solvent evaporates, extra heat is required, and it takes time to reach the amount of transpiration at which a stable insecticidal effect can be obtained.
On the other hand, the drug-containing substance for heat evaporation of the present invention does not use any solvent or uses it at the minimum necessary, so that the drug component is always supplied to the heated portion of the drug-containing substance during heating. In addition, since only the drug component is evaporated, stable drug evaporation can be obtained from the beginning of use. In addition, since the heat required to evaporate the solvent is not required, the drug-containing body is quickly heated immediately after the power is applied to the heating element, and the rising of the drug evaporation becomes very good. A stable insecticidal effect can be obtained.

Further, the heat evaporation method of the present invention differs from the conventional heat absorption and evaporation method of the chemical liquid absorption type in that it does not use an organic solvent solution of the drug, and therefore does not require a chemical liquid container and does not cause liquid leakage. In addition, a very compact design can be achieved, and the drug can be evaporated by simply heating the solid drug-containing substance containing the drug, so that the danger of fire can be avoided and the safety can be improved. In addition, the drug substance for heat evaporation of the present invention uses only the drug component or the minimum necessary amount even when a solvent is used, so that the adverse effect on the atmosphere due to the evaporation of the solvent can be significantly reduced. It becomes possible.

[0015]

Aspects of the present invention contain a drug substance for heat evaporation.
As stability improver for heat, stearyl -β-
(3,5-di-t-butyl-4-hydroxyphenyl)
Propionate (hereinafter abbreviated as AA-1), 2,
2′-methylenebis (4-methyl-6-t-butylphenol) (hereinafter abbreviated as AA-2) , 4,4′-thiobis (3-methyl-6-t-butylphenol) (hereinafter AA- 3 ) Abbreviated) , tetrakis- [methylene-
3- (3 ', 5'-di-t-butyl-4'-hydroxyphenyl) propionate] methane (hereinafter abbreviated as AA- 4 ) , triethylene glycol-bis [3- (3
-T-butyl-5-methyl-4-hydroxyphenyl)
Propionate] (hereinafter abbreviated as AA- 5 ), 1,
6-hexanediol-bis [3- (3,5-di-t-
Butyl-4-hydroxyphenyl) propionate]
(Hereinafter abbreviated as AA- 6 ), N, N'-hexamethylenebis (3,5-di-t-butyl-4-hydroxy-
Hydrocinnamamide) (hereinafter abbreviated as AA- 7 ),
2,2-thio-diethylenebis [3- (3,5-di-t
-Butyl-4-hydroxyphenyl) propionate]
(Hereinafter, abbreviated as AA- 8), tris - (3,5-di -t- butyl-4-hydroxybenzyl) - isocyanurate (hereinafter abbreviated as AA- 9) or we selected specific compound Characterized in that at least one or more of the above is contained in the drug-containing substance. The compound (AA-1 to AA- 9 )
May be used alone or in combination of two or more. The amount used is usually 10 parts by weight or less, preferably 0.1 to 8 parts by weight, based on 100 parts by weight of the drug. The effect of preventing clogging of the body for a long period of time is obtained.

The compound (AA-1 to AA- 9 ) may be contained in the drug-containing substance by adding it to the base material before molding the drug-containing substance and mixing. In addition , in order to improve the permeability and diffusibility of the drug into the drug-containing substance, etc., the compound may be dissolved and contained in a dissolution aid for the specific compound or a minimum necessary solvent used as a dispersing solvent. As the solvent, for example, an aliphatic saturated hydrocarbon and unsaturated aliphatic hydrocarbon solvent can be used. Other, water,
Alcohols, glycol ethers such as ethylene glycol monobutyl ether and the like, glycols, esters such as isopropyl myristate and butyl stearate can also be used. In this case, the amount of the solvent used is preferably 10 parts by weight or less based on 100 parts by weight of the drug. Meanwhile, agents that transpiration is impregnated with the drug in the drug-containing material before molding of the substrate, may be followed by molding the drug-containing body.

The inorganic powder and / or organic powder used as the base material of the heat-evaporating drug-containing substance of the present invention includes calcium hydrogen phosphate and its anhydride, calcium phosphate and its anhydride, calcium phosphate-based apatite, and metasilicate aluminate. Magnesium, hydrotalside, aluminum hydroxide gel, aluminum magnesium magnesium,
Calcium carbonate, aluminum silicate, magnesium silicate, silicic anhydride, clay, diatomaceous earth, kaolin, colloidal silica, water glass, aluminum phosphate, magnesium phosphate, gypsum, magnesia cement, tungsten, zinc oxide, bengara Inorganic powders such as tungsten oxide and zirconium oxide; fluorine-based resins such as PTFE (ethylene tetrafluoride resin) and PVdF (vinylidene fluoride resin); polyacetal, polyarylate, polyetheretherketone, polyethylene, polyethylene Polysulfones such as terephthalate, polycarbonate, polyamides such as nylon 6, nylon 66, nylon 11, nylon 12, aromatic nylons and copolymers thereof, polyimides, polyamide imides, polysulfones, polyethersulfones, etc. Fat, Porifueniren'e - ether, polyphenylene sulfide, polybutylene terephthalate -
And organic powders such as polypropylene, polymethylpentene, AES resin, AS resin, ABS resin, MBS resin, crystalline cellulose, CMC, MC, starch, HPMC, HPC, and HPS.

The heat-evaporating drug-containing substance of the present invention can be prepared by mixing the above-mentioned specific compound with an inorganic powder and / or an organic powder and subjecting the mixture to a method such as compression molding or extrusion molding. Is not particularly limited. In addition, the shape of the heat-evaporating drug-containing substance of the present invention is arbitrary, such as a flat plate, a donut, and a column, and is selected according to the shape of the heating portion of the heating element and the evaporability of the drug. In the case where a thermoplastic resin powder is used among the organic powders, it is possible to improve the strength of the drug-containing material by heating and fusing the resin-containing material near the melting point of the thermoplastic resin powder after molding. That is, by melting the contact portion of the thermoplastic resin powder in a state where the thermoplastic resin powder is in close contact with the inorganic powder and / or the organic powder, the strength against breakage and cracking can be improved without losing porosity. Further, since the thermoplastic resin powder is excellent in water resistance and moisture resistance, it does not show a decrease in strength even at high humidity, so that stable quality heating that maintains a constant strength even under general use environment is achieved. It is possible to mold the transpiration drug-containing body. In addition, since the thermoplastic resin powder is stable to water, the use of the heat-evaporation agent-containing substance of the present invention makes it possible to use a water-based deodorant, a fungicide, a fungicide, an insecticide, and a fragrance. It becomes possible to evaporate the properties and the emulsified drug solution.

Further, the heat-evaporating drug-containing material of the present invention contains powder having fluidity and lubricity during compression molding and extrusion molding.
In order to improve the lubricity, if necessary as a lubricant within the range that does not impair the properties of the heat-evaporating drug-containing body, as a lubricant,
Talc, stearates such as magnesium stearate and sodium stearate, amino acid-based lubricants such as N-lauryl-DL-aspartic acid-β-lauryl ester and N ⁶ -lauroyl-L-lysine, boric acid, and liquid paraffin And waxes such as sodium benzoate and carbowax. Further, a fibrous powder such as glass fiber or carbon fiber may be added to improve the strength of the heat-evaporating drug-containing substance. Additives such as pigments, dyes, preservatives, stabilizers, ultraviolet absorbers, flame retardants, and accidental corrosion inhibitors are added to the heat-evaporation agent-containing substance as needed as long as the properties are not impaired. You may.

The heat-evaporating drug-containing material of the present invention is porous and its porosity is usually 15 to 60%, preferably 20 to 50%, so that a stable evaporative effect over a long period of time can be obtained. Can be achieved. That is, when the porosity is less than 15%, the transfer of the drug in the heating-evaporation drug-containing body is not performed smoothly. Therefore, the evaporation of the drug in the heated portion of the drug-containing material and the supply of the drug to the heated portion are not performed. It is not preferable because the balance is poor and stable evaporation of the drug is difficult to obtain. On the other hand, 6
A porosity of 0% or more is not preferred because thermal conductivity becomes poor and it becomes difficult to evaporate the drug at low temperatures.

The heat-evaporation drug-containing body of the present invention comprises an insecticide,
For the purpose of sterilization, deodorization, aroma, and the like, it can be suitably used as a heat-evaporation drug-containing substance of a heat-evaporation device for heat-evaporation of various insecticides, disinfectants, deodorants, and fragrances. FIG. 1 shows an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention. In the figure, reference numeral 1 denotes a heating-evaporation drug-containing body according to the present invention, which is used by being placed on a heating element 3 of a heating device 2. FIG. 2 shows another embodiment of the heat-evaporation drug-containing material. This drug-containing substance for heat evaporation comprises a drug-containing substance 1 and a container 4 containing the same. The container 4 further includes two members, an upper container 5 and a lower container 6, and a plurality of ribs 7 for supporting the drug-containing substance on its inner surface.
Are formed. Further, ventilation holes 8 and 9 are formed in the center portions of the upper container 5 and the lower container 6, respectively. A projection 10 is formed on the outer surfaces of the upper container 5 and the lower container 6 so that a gap is formed between the container 4 and the heating element when the container is placed on the heating element, and the space is heated indirectly. Has been established. Note that, without forming the protruding portion 10, the container 4 may be directly placed on the heating element and may be indirectly heated via the bottom wall of the lower container 6. The ribs 7 are provided between the inner surfaces of the upper container 5 and the lower container 6 and the medicine-containing body 1.
As a result, a gap X is formed, and the medicine evaporated by heating flows more smoothly toward the opening 11. Although what is shown above is an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention, it is needless to say that apparatuses of various shapes can be used without being limited thereto. Alternatively, a configuration may be adopted in which a heat conductive member is provided on the heating element, and the drug-containing body is heated by the heat conducted to the heat conductive member.

It is desired that the material of the container holding the drug-containing material has heat resistance and chemical resistance according to the drug used. For example, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, polyacetal, melamine resin, polytetrafluoroethylene, phenolic resin, unsaturated polyester resin, epoxy resin, urethane resin, methacrylic acid resin, polyarylate, Examples thereof include polyketone, polyamideimide, polyallyl sulfone, polyphenylene sulfide, polyphenyl sulfone, and polyether nitrile. The shape of the container is selected according to the shape of the drug-containing substance for heat evaporation. Also figure
A container may not be used as in the usage mode shown in FIG.

The heating temperature when using heating is as follows:
Although it is selected according to the medicine to be contained, it is usually preferable to keep the surface temperature of the heated portion of the heat-evaporation medicine-containing body at 50 ° C to 150 ° C, regardless of whether a container is used or not. More preferably, the temperature is 70 ° C to 120 ° C. Examples of the heat generating method of the heating element include a method of energizing a heater using a resistance heater (such as a nichrome wire) and a semiconductor (PTC), an oxidation reaction (oxidation of a metal such as iron and magnesium), and a hydrolysis reaction (quick lime). Reaction with water, etc.)
A method using combustion heat of gas, kerosene, wax, or the like, a combustion heat of alcohol, gas, or the like using a platinum catalyst, and a method of directly or indirectly using other heat sources are used.

The heat-evaporating drug-containing body of the present invention can contain various heat-evaporable drugs depending on the purpose of use. For example, when used for the purpose of insecticide, as the insecticide, various conventionally used heat transpirable insecticides can be used, and examples include pyrethroid-based insecticides, carbamate-based insecticides, organophosphorus-based insecticides, and the like. be able to. In general, pyrethroid insecticides are preferably used because of their high safety. For example, allethrin (hereinafter referred to as AB-
1), d1.d-T80-aresulin (hereinafter, abbreviated as AB-2), d.d-T80-aresulin (hereinafter, abbreviated as AB-3), d.d-T80-praletrin ( Hereinafter, AB-4), phthalthrin (hereinafter, abbreviated as AB-5), d-T80-resmethrin (hereinafter, abbreviated as AB-6), d-T80-framethrin (hereinafter, AB-7) Abbreviated), permethrin (hereinafter abbreviated as AB-8), phenothrin (hereinafter abbreviated as AB-9), fenvalerate (hereinafter abbreviated as AB-9)
AB-10), cypermethrin (hereinafter AB)
-11), cyphenothrin (hereinafter AB-1)
2), empentrin (hereinafter abbreviated as AB-13), terrareslin (hereinafter abbreviated as AB-14), etofenprox (hereinafter abbreviated as AB-15), benfluthulin (hereinafter abbreviated as AB- 16) can be used. Similarly, when used for the purpose of fragrance, various natural and artificial flavors can be used,
For example, animal and vegetable natural flavors, hydrocarbons, artificial fragrances such as alcohols, phenols, aldehydes, ketones, lactones, oxides, esters and the like.
The seeds can be used alone, or two or more can be used as a mixture. Furthermore, depending on the purpose, deodorant, bactericide,
Various chemicals such as anti-binders, rust preventives, acaricides, repellents and the like can be used as long as they evaporate by heating.
The content of the drug is 1 to 30 per 100 parts by weight of the drug-containing substance.
It is preferable to include the parts by weight.

[0025]

The present invention will be specifically described below with reference to examples and comparative examples. Examples 1 to 24 95 parts by weight of anhydrous calcium hydrogen phosphate and 5 parts by weight of microcrystalline cellulose were mixed with the compounds shown in Table 1 below, and the mixture contained a flat solid drug under a pressing pressure of 50 kg / cm ² in a press machine. Body (size 30 × 18 × 6.5mm, weight 6.0)
g) was prepared. A predetermined amount of the chemicals shown in Table 1 below was contained therein by immersion to obtain a heat-evaporating drug-containing substance of the present invention (Examples 1 to 24).

Comparative Examples 1 to 3 As shown in Table 1 below, Comparative Examples 1 to 3 were obtained in the same manner as in Examples 1 to 24 except that the compounds AA-1 to AA- 9 were not added and mixed.

[Table 1]

Test Example 1 (Evaporation Test) The drug-containing substances produced in Examples 1 to 24 and Comparative Examples 1 to 3 were each set in a heating evaporator shown in FIG. Electricity was supplied to the heating element to heat the surface of the drug-containing body to 90 ° C. ± 5 ° C., and the amount of drug evaporated at each heating time was measured. Table 2 shows the results. In addition, the amount of transpiration was measured as follows. Evaporation amount: Evaporation chemicals were trapped at regular intervals for 1 hour in a silica gel packed column, extracted with acetone, concentrated, and quantitatively analyzed by gas chromatography.

[Table 2]

As is evident from the results shown in Table 2, the drug-containing substance not containing the specific compound of the present invention as in Comparative Examples 1 to 3 gradually clogged as the heating time elapsed. The amount of drug transpiration decreased, dropped to less than half of the initial transpiration at 180 hours, and the drug stopped evaporating at 240 hours. However, when a drug-containing substance containing the specific compound of the present invention was used as in Examples 1 to 24, in the heating use for as long as 300 hours, the evaporation of the drug was not suppressed, and the drug was stabilized. Drug transpiration was obtained.

Examples 25-30 90 parts by weight of anhydrous calcium hydrogen phosphate and nylon 12
10 parts by weight of powder and the compounds shown in Table 3 below were mixed, and a flat solid drug-containing substance (size 30 × 18 × 7 mm, weight 6.0 g) was pressed with a press at a pressing pressure of 50 kg / cm ^2. Prepared. A predetermined amount of the chemicals shown in Table 3 below was contained therein by immersion to obtain a heat-evaporating drug-containing substance of the present invention (Examples 25 to 30).

[Table 3]

Comparative Examples 4 and 5 As a control, Comparative Example 4 in which a drug was dissolved in a hydrocarbon solvent (about 1200 mg of dl.d-T80-aresulin)
/ 45 ml) and Comparative Example 5 (containing about 300 mg of dd-T80-praletrin / 45 ml), a commercially available heat-absorbing heat-absorbing agent of a chemical solution.

Test Example 2 (Efficacy Test) The drug-containing bodies produced in Examples 25 to 30 were set in the heating evaporator shown in FIG. 12 hours per day, equivalent to the first day of energization of the heating element (no energization before test), equivalent to the second day of energization (12 hours of energization before test), equivalent to 10 days of energization (108 hours of energization before test), energized Equivalent to the 20th day (228 hours before energization before test)
(48 hours), the knockdown effect on adult Culex pipiens was examined. The energization before the test is 12
The energization for 12 hours and the non-energization for 12 hours were repeated, and the surface of the drug-containing substance was exposed to 90 ° C. ± 5 ° C. in Examples 25 to 28, and to Examples 29 to 3
0 was heated to 80 ° C. ± 5 ° C. The sample which had been energized for a predetermined time before the test was placed in the center of the lower surface of an 8-tatami room, and 1 hour after the energization was started, 1
After releasing 00, the number of knockdown insects with the passage of time was confirmed, and the time (KT-50) at which 50% of the insects fell and turned was measured. Moreover, it carried out similarly about the comparative example. Table 4 shows the results.

[0032]

[Table 4] As is clear from the results shown in Table 4, in the case of the comparative example, on the first day of energization, the transpiration of the drug was not sufficiently performed, and it took 8 to 9 minutes for the insecticidal effect to appear. . On the other hand, the drug-containing substance of the present invention has two
An insecticidal effect was obtained in a short time of about 3 minutes. In addition, a stable insecticidal effect was obtained over 30 days, which exceeded the comparative example in all elapsed days, indicating that a quick insecticidal effect was obtained immediately after energization.

[0033]

As described above, the present invention relates to a drug containing a specific compound, based on an inorganic powder and / or an organic powder, and containing only a heat-evaporable drug component or a minimum necessary amount of a solvent. Since the drug is evaporated by directly or indirectly heating the inclusion using the inclusion, the following effects and advantages can be obtained. B) By using a base material containing a specific compound at a quantitative ratio that exhibits the effect of preventing clogging of the drug-containing substance but does not suppress the evaporation of the drug, it is possible to minimize or eliminate the use of a solvent. A drug is contained, and an effective and stable drug evaporation effect can be obtained for a long period without clogging. B) Since only the drug component is evaporated, the thermal efficiency is good, and the rise of the drug evaporation is very good. In the case of the insecticide, a quick insecticidal effect can be obtained immediately after energization of the heating element. Further, the power consumption of the heating element is small, energy can be saved, for example, a small-capacity power source such as a dry battery can be used, and the heating device can be made compact and portable. C) The use of minimal or no solvents is required, avoiding the danger of fire, improving safety, and significantly reducing volatile organic compounds. The adverse effects can be reduced. The advantage of resource saving is also obtained. D) Since the drug is evaporated using only the drug or a solid drug-containing substance that is contained together with a minimum amount of a solvent, a drug solution container is not required unlike the conventional drug solution absorption type. Therefore, there is no problem such as liquid leakage, and a very compact design can be achieved, and resource saving and cost reduction can be achieved. E) Since only the drug is evaporated, the thermal efficiency is good,
The temperature of the heating element can be reduced. Therefore, the danger of burns can be avoided and safety can be improved.

[Brief description of the drawings]

FIG. 1 is a schematic cross-sectional view showing an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention, omitting an internal structure of the heating apparatus.

FIG. 2 is a cross-sectional view showing another use mode of the heat-evaporation drug-containing body of the present invention.

[Explanation of symbols]

 1 Drug-containing substance for heat evaporation 2 Heating device 3 Heating element

──────────────────────────────────────────────────続 き Continuation of front page (56) References JP-A-53-121927 (JP, A) JP-A-55-164603 (JP, A) JP-A-54-28818 (JP, A) JP-A 63-121 152305 (JP, A) (58) Field surveyed (Int. Cl. ⁷ , DB name) A01N 25/18 103 A01N 25/18 101 A01M 1/20 A01N 25/08

Claims (3)

(57) [Claims] 1. A mineral powder and / or organic powders, and both the one or more heating transpiration agent components, cheap to drugs, heat
Stearyl -β- as qualitative improvement agent (3,5-di -t-
Butyl-4-hydroxyphenyl) propionate,
2,2'-methylenebis (4-methyl-6-t-butylphenol) , 4,4'-thiobis (3-methyl-6-
t-butylphenol) , tetrakis- [methylene-3
-(3 ', 5'-di-tert-butyl-4'-hydroxyphenyl) propionate] methane , triethylene glycol-bis [3- (3-tert-butyl-5-methyl-4-)
Hydroxyphenyl) propionate], 1,6-hexanediol-bis [3- (3,5-di-t-butyl-
4-hydroxyphenyl) propionate], N, N '
-Hexamethylenebis (3,5-di-t-butyl-4-
Hydroxy-hydrocinnamamide), 2,2-thio-diethylenebis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionate] , tris- (3
5-di -t- butyl-4-hydroxybenzyl) - the isocyanurate DOO or we selected at least one kind of mixture containing at a rate of less than 10 parts by weight relative to the heating transpiration agent 100 parts by weight of the compound A drug-containing body for long-term heat evaporation, which is a press-formed body. 2. The heat-evaporable drug component is added in a weight of 10 parts without using a solvent or 100 parts by weight of the drug component.
The drug-containing substance for long-term heat evaporation according to claim 1, wherein the substance is contained together with a solvent in an amount of not more than part by weight . 3. An inorganic powder and / or an organic powder , and at least one heat-evaporable drug alone or 100% by weight of a drug component.
Together with the solvent in a proportion of 10 parts by weight or less ,
Stearyl-.beta.-(3 as stability improver for heat,
5-di-t-butyl-4-hydroxyphenyl) propionate, 2,2'-methylenebis (4-methyl-6-
t-butylphenol) , 4,4'-thiobis (3-methyl-6-t-butylphenol) , tetrakis- [methylene-3- (3 ', 5'-di-t-butyl-4'-hydroxyphenyl) propionate Methane , triethylene glycol-bis [3- (3-t-butyl-5-methyl-4-hydroxyphenyl) propionate],
1,6-hexanediol-bis [3- (3,5-di-
t-butyl-4-hydroxyphenyl) propionate], N, N'-hexamethylenebis (3,5-di-t
-Butyl-4-hydroxy-hydrocinnamamide),
2,2-thio-diethylenebis [3- (3,5-di-t
- butyl-4-hydroxyphenyl) propionate], tris - (3,5-di -t- butyl-4-hydroxybenzyl) - heat transpiration agents 100 weight of at least one or more isocyanurate bets or we selected compounds Pressure of a mixture containing 10 parts by weight or less per part by weight
The surface of the heat-evaporating drug-containing body, which is a molded product, is 50 to 15
A method for heating and evaporating a drug, comprising heating at 0 ° C. to evaporate the drug.